All types of blood cell of the body are continuously produced by rare pluripotent self-renewing HSCs (haemopoietic stem cells) by a process known as haemopoiesis. This process provides a valuable model for examining how genetic programmes involved in cell differentiation are established, and also how cell-fate specification is altered in leukaemia. Here, we describe examples of how miRNAs (microRNAs) can influence myelopoiesis and how the identification of their target mRNAs has contributed to the understanding of the molecular networks involved in the alternative control between cell growth and differentiation. Ectopic expression and knockdown of specific miRNAs have provided powerful molecular tools able to control the switch between proliferation and differentiation, therefore providing new therapeutic tools for interfering with tumorigenesis.
Introduction
HSCs (haemopoietic stem cells) reside in the bone marrow and give rise to progenitors that become progressively restricted to several or single blood cell lineages [1] . These progenitors are devoted to the production of mature blood cells, including red blood cells, megakaryocytes, granulocytes, monocyte/macrophage cells and lymphocytes. All the non-lymphoid lineages of the blood are indicated as myeloid lineages. However, in its most common usage 'myeloid cells' refers to granulocytes (neutrophils) and monocytes. Circulating monocytes may then migrate to tissues where they differentiate into macrophages.
Granulocytes (neutrophils) and monocytes/macrophages develop by progenitors that include CMPs (common myeloid progenitors) and, subsequently, GMPs (granulocyte/ macrophage progenitors) in a process known as myelopoiesis. The production of these two alternative lineages depends on the unique combination and relative expression levels of key transcription factors that promote competing specific genetic programmes [2] . In particular, the co-ordinated development of myeloid cells depends on reciprocal inhibitory effects and adjustment of the concentration of key transcription factors that are responsible for the reduction in cell proliferation, induction of apoptosis and the expression of lineage-specific myeloid genes. Among master transcription factors for myelopoiesis are C/EBPs (CCAAT/enhancer-binding proteins), PU.1, GFI1 (growth-factor independent 1), IRFs (interferon-regulatory factors), SCL (stem-cell leukaemia factor; also known as TAL1) and RUNX1 [runtrelated transcription factor 1; also known as AML1 (acute myeloid leukaemia 1)]. A remarkable feature of transcription factors in the myeloid system is that in human AML (acute myeloid leukaemia) the majority of them are involved in chromosomal translocations or contain somatic mutations [2, 3] . In AML, the accumulation of leukaemic cells (also referred to as blasts) arises from a failure of myeloid progenitors to mature, and therefore AML are classified in subtypes based on the stage at which normal differentiation is blocked in the leukaemic blasts [2, 3] . miRNAs (microRNAs) provide an additional level of control beyond the transcription factors. They modulate a variety of developmental and physiological processes by regulating translation and stability of specific mRNAs [4] . A single miRNA can control the levels of hundreds of different target genes. Beyond its mere presence or absence, the concentration at which a given factor is expressed may influence lineage choice and differentiation. For this reason, it has been hypothesized that miRNAs deeply contribute to the large network of factors that dictate haemopoietic cell lineage specification. Indeed, several miRNAs are highly expressed in specific haemopoietic lineages and manipulation of their levels has been correlated with changes in cellular properties or differentiation [5] . Moreover, similarly to transcription factors, they have been found mutated or altered by chromosomal translocations associated with leukaemia [6] . Here, we will provide examples of miRNAs with defined roles in myelopoiesis.
miRNA-mediated molecular circuitries in granulocytic differentiation
APL (acute promyelocitic leukaemia) represents a powerful in vitro model system to study granulopoiesis [2, 3, 7] . APL ATRA-treated NB4 cells were analysed for miRNA expression by miRCURY LNA Array Oligoset covering 526 human miRNAs annotated in MiRBase 8.1. Raw data were normalized after background subtraction using global median of the intensities.
In the histograms, the results are presented as fold change of miRNA expression with respect to its control (untreated cells) at each time point. Northern blots on different miRNAs are shown.
is characterized by chromosomal translocations involving the RAR (retinoic acid receptor) gene resulting in clonal expansion of haemopoietic precursors blocked at the promyelocitic stage of differentiation. The treatment of APL cells with ATRA (all-trans retinoic acid) overcome this block and induces granulocytic differentiation as shown by morphological changes and increased expression of surface antigens.
Analysis of miRNA expression is an important step in elucidating miRNA function. Using a miRNA microarray platform, we initially compared the miRNA expression profiles of an ATRA-treated APL cell line (NB4) with those of untreated cells at the same time point. We identified a small number of miRNAs up-regulated upon ATRA treatment of APL cell lines (Figure 1 ), most of which might target genes involved in haemopoietic differentiation.
The mechanism by which ATRA regulates miRNA expression is largely uncharacterized. We hypothesized that miRNAs expression could be regulated in part by ATRAmodulated transcription factors. In fact, we demonstrated that miR-223 is induced by ATRA treatment through the transcription factor C/EBPα [8] . C/EBPα is a key player in myelopoiesis as it regulates many myeloid cell-specific genes and promotes granulocyte-specific genes at the expense of the monocytic differentiation programme. miR-223 activation correlated in time with the decrease in accumulation of the NFI-A (nuclear factor 1/A) transcription factor ( Figure 2) ;
Figure 2 Role of miR-223 and miR-424 in myeloid differentiation
A common myeloid precursor gives rise to mature granulocytes and monocytes. Granulocytes and monocytes/macrophage production depends on the activity of several transcription factors. A crucial role in the initial steps of myelopoiesis is played by C/EBPα and PU.1. These two factors are responsible for the transcriptional activation of miR-223 and miR-424 respectively that down-regulate the common target NFI-A. NFI-A counteracts the differentiation of both granulocytes and monocytes, thus its down-regulation is important for myelopoiesis to proceed.
this, together with the experimental validation of the bona fide target site in the 3 -UTR (untranslated region), indicated NFI-A as a target of miR-223. Interestingly, the NFI-A protein was previously implicated in replication as well as in controlling differentiative processes [9, 10] and its knockdown was shown to enhance granulocytic differentiation [8] . An in silico search in the miR-223 promoter revealed also the presence of an NFI-A site overlapping one of the two C/EBPα-binding sites. ChIP (chromatin immunoprecipitation) experiments demonstrated that this factor does indeed bind the miR-223 promoter but only in the absence of retinoic acid. Since NFI-A is also the target of miR-223, a very interesting autoregulatory loop appears to control granulocytic differentiation of APL cells: C/EBPα activation produces the displacement of NFI-A from the miR-223 promoter and its up-regulation. In cascade, miR-223 acts by repressing NFI-A thus removing it from the competition with C/EBPα and maintaining sustained levels of miR-223 expression [8] .
Naturally, NFI-A is just one among hundreds of possible miR-223 targets. Even if it appears to be a critical target gene for myeloid differentiation, the circuit described may represent only one aspect of miR-223's full molecular effects. Indeed, knocking down NFI-A levels by RNAi (RNA interference)-activated differentiation-specific genes such as G-CSFr (granulocyte colony-stimulating factor receptor) enhanced granulocytic differentiation only in the presence of ATRA, while ectopic expression of miR-223 was effective alone [8] . For this reason, it is crucial to elucidate the full network of targets regulated by a single miRNA.
Recently, down-regulation of miR-223 has been shown to occur selectively in AML patients that carry the t(8;21) chromosome translocation, which is responsible for the production of the fusion protein AML1-ETO (eight twenty-one) and it has been shown that the AML1-ETO protein inhibits miR-223 expression through its binding to the promoter region [11] . This indicates that the deregulation of miR-223 may contribute to the differentiation block underlying myeloid leukaemia pathogenesis and reveals miRNAs as additional molecular targets for therapeutic intervention in leukaemia.
A miRNA profile similar to the one described above has been reported independently [12] . The authors showed that the up-regulated miRNAs miR-107, miR-15/ miR-16 and let-7 target the NFI-A, Bcl-2 and Ras transcripts respectively. All these genes have defined roles in cell proliferation, differentiation and tumorigenesis [12] . Moreover, it was shown that the induction of let-7a-3/let-7-b cluster relies on the binding of NF-κB (nuclear factor κB) in the promoter region.
A germline miR-223 in knockout mouse has been recently produced [13] . Strikingly, the presence of miR-223 is dispensable for granulocyte cell-fate specification and its absence produced an increase of granulocyte progenitors and altered granulocyte immunological function. This suggests that in vivo other players might compensate for the absence of miR-223 in the initial steps of granulocytic differentiation. Alternatively, it is also possible that different phenotypes can be obtained depending on the specific differentiation time at which miRNA depletion is produced. The transcription factor Mef2c has been identified as a crucial target of miR-223 in mouse myeloid precursors and indeed conditional knockout of Mef2c within the miR-223 knockout mouse rescued the proliferation abnormality but not the differentiation defect and the functionality of granulocytes, suggesting that additional targets of miR-223 may be involved in these phenotypes [13] .
miRNA-mediated molecular circuitries in monocytic differentiation
Towards studying the molecular circuitries regulated by miRNAs and involvement in the control of myelopoiesis, we have identified a new pathway by which the master haemopoietic transcription factor PU.1 regulates human monocytic differentiation.
Whereas ATRA treatment induces differentiation of APL to morphologically and functionally mature granulocytes, PMA or vitamin D induces a monocyte/macrophage phenotype of these cells. miR-424 was previously identified among the miRNAs up-regulated by PMA-induced monocyte/ macrophage differentiation of a human leukaemia cell line [14] .
We have shown that the transcription of miR-424 is activated by the master myeloid transcription factor PU.1 and this up-regulation appears to be involved in stimulating monocytic differentiation through miR-424-dependent translational repression of NFI-A (Figure 2 ) [15] . In turn, the decrease in NFI-A levels is important for the activation of differentiation-specific genes such as M-CSFr (macrophage colony-stimulating factor receptor). In line with these data, both RNAi against NFI-A and ectopic expression of miR-424 enhance monocytic differentiation. The interplay among these three components was found in APL cell lines as well as in culture of HPCs (human CD34 + progenitor cells) differentiating selectively through the monocyte/macrophage lineage [15] .
These results point to the important role of miRNAs in conjunction with master transcription factors in haemopoietic differentiation and indicate the crucial role of NFI-A in counteracting the monocytic differentiation programme [15] .
Recently, another miRNA-mediated molecular circuitry involved in monocytic differentiation of CD34 + HPCs has been characterized [16] . This study showed that the miR-17-5p-92 cluster is down-regulated during cytokine-induced monocytopoiesis. This produces the up-regulation of their target gene AML1 and, as a consequence, the transcriptional activation of the M-CSFr. Similarly to the minicircuitry identified for miR-223 and NFI-A, AML1 binds to the miR-17-5p-92 cluster promoter and inhibits miRNA transcription, thus generating a negative regulatory loop. Notably, mouse haemopoiesis occurring in the absence of the miR-17-92 cluster produces normal amount of monocytes and other haemopoietic cells such as red blood cells, granulocytes and T-cells but leads to an isolated defect in B-cell development [17] .
miRNAs and AML
miRNAs have been found altered and in some cases mutated by chromosomal translocations associated with leukaemia, and it has been suggested that miRNAs might play an important role in the molecular pathogenesis of AML interfering with pathways essential for myeloid differentiation [6] . Moreover, miRNA signatures are associated with defined cytogenetic subgroups and outcome in AML [18] [19] [20] . Experimental studies indicate that miRNAs can function either as tumour suppressor genes or as oncogenes in leukaemia. The use of expression system for the replacement of tumour suppressor miRNAs and antisense oligonucleotides to inhibit oncogenic miRNAs may ultimately be clinically useful in the treatment of leukaemia. In conclusion, it is now clear that miRNAs represent a class of genes with a great potential for use in diagnosis, prognosis and therapy of AML.
Concluding remarks
Despite the increasing data obtained from in vitro cell systems showing the involvement of miRNA in myelopoiesis [8, 11, 15, 16] , knockout of these miRNAs in the mouse haemopoietic system did not always match the expected results [13, 17] . This may be due to several reasons: (i) in vitro differentiation of haemopoietic progenitor cells may not fully recapitulate the complex networks of gene expression changes occurring in haemopoiesis in vivo; (ii) the timing of miRNA manipulation may be critical for establishing the specific phenotypic differences observed in vivo and in vitro; (iii) although mice have been, beyond doubt, useful in studying human haemopoiesis, there are some subtle but significant differences between human and mouse haemopoietic gene regulation [21] . Therefore, much more work will be necessary in order to assign specific functions to miRNAs along the production of different haemopoietic lineages. 
